Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Observes outcomes in people with relapsed or refractory acute myeloid leukemia

Follows people with acute myeloid leukemia that has returned or not responded to treatment.

Plain-language title generated from the registry record
Registry title: Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Key facts

Where
Aachen, Greifswald, Halle, and Rostock, GermanySee the 4 sites

Where in Germany

  • University Hospital AachenAachen, GermanyTaking people
  • University Hospital GreifswaldGreifswald, GermanyTaking people
  • University Hospital HalleHalle, GermanyTaking people
  • University Hospital of RostockRostock, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Trial code
NCT06459024
Record updated
27 October 2026
Original description
This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sitesRead full original descriptionShow less

Master Framework For Relapse or Refractory Acute Myeloid Leukemia- IMPACT STREAM - A Prospective Observational Study of Treatment Outcomes

This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sites

Inclusion: Patients with AML diagnosis according to WHO2022 or ICC2022; Treatment failure (i.e. relapse, refractory or progression, including MRD) according to ELN2022 criteria; Participant or his/her legal representative is willing and able to give informed consent for participation in the study.

Exclusion: Patients included in clinical trials may be enrolled except where otherwise specified in the experimental protocol.

ClinicalTrials.gov NCT06459024